Book Appointment
Subscribe to out newsletter today to receive latest news administrate cost effective for tactical data.
A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects
(CANOPY-1)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study of Durvalumab Monotherapy or in Combination with Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
(EMERALD-2)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1))
A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatmet in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA)
EPIK-B3: A Phase III, multicenter, randomized, double-blind,
placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2)
A Multicountry, Multicentre, Noninterventional, Retrospective Study to Describe the Real-world Management Outcomes in Patients with Unresectable Hepatocellular Carcinoma. (OREIOS)
A descriptive study of PIK3CA mutations in patients with HR+/Her2-advanced breast cancer (PIK3CA Registry Study)
A Prospective, Multicenter, Non-Interventional, Observational, Real-World Study to Evaluate the Safety, Adherence to Therapy, and Effectiveness of a T-DM1 Antibody-Drug Conjugate Biosimilar in Indian Patients with HER2-Positive Early Breast Cancer
A phase III, multicenter, randomized, double blind, placebo controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm
N2) completely resected (R0) non-small cell lung cancer (NSCLC) (CANOPY A)
A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant / Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)
A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation- Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2).
SINGLE ARM STUDY TO EVALUATE THE SAFETY OF DACOMITINIB FOR THE FIRST LINE TREATMENT OF PARTICIPANTS IN INDIA WITH METASTATIC NON SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ACTIVATING MUTATIONS
“SINGLE-ARM STUDY TO EVALUATE THE SAFETY OF LORLATINIB IN ALK INHIBITOR-TREATED UNRESECTABLE ADVANCED AND/OR RECURRENT ALK-POSITIVE NON-SMALL CELL LUNG CANCER PARTICIPANTS IN INDIA”
“A Phase III Double-blind Randomized Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer(TNBC) (Capitello290)”
“A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Regional, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers (TOPAZ-1)”
A prospective , Multicentre, Phase -IV Clinical Trial of Olaparib in the Indian Patients with Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following Platinum Based Chemotherapy and Metastatic Breast Cancer with Germline BRCA 1/2 Mutation (Soli Study)
A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (PAPILLON)
A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an ORAL SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (SERENA-4)
A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T DXd) Versus Investigator’s Choice Chemotherapy in HER2 low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY Breast06)
A Randomised, Double-blind, Placebo-controlled, Phase III Study of Olaparib Maintenance Monotherapy in Patients with BRCA Wild Type Advanced (FIGO Stage III-IV) High Grade Serous or Endometriod Ovarian Cancer Following Response to Standard First-line Platinum-based Chemotherapy (MONO-OLA)
“A Phase III, Randomised, Double blind, Placebo controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-Small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum based Concurrent Chemoradiation Therapy (PACIFIC-8)
Prevalence of BRCA1 and BRCA2 Mutation Among Indian Breast Cancer Patients: A Multicenter Cross-Sectional Study
A prospective, multicenter, Phase-IV clinical trial to assess safety of Durvalumab in Indian adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) and urothelial cancer.
A Phase IV ,Multicenter,Open Label,single Arm study of Paertuzumab(In combination of Trastuzumab with Docetaxel)In 1st line treatment of Indian Patients with Her 2 Positive Advanced(Metasatic or Locally recurrent)Breast Cancer.
A Phase III, randomized study of Oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged(ALK Positive),IIIB or IV,non squamous non small cell lung cancer.
An Open Label, Single Arm, Multicenter, Safety Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
An Open Label , Randomized, Multicenter, phase 2, Safety Study and efficacy study of Capmatinib (INC 280) plus Pembrolizumab versus Pembrolizumab alone in locally Advanced Or Metastatic non small cell lung cancer.
A Multicenter Phase 4, Open-label, single-arm, Safety and Efficacy Study of Enzalutamide in Indian patients with Progressive Metastatic
Castration-Resistant Prostate Cancer (9785-CL-0413)
RANDOMIZED, OPEN LABEL, MULTICENTER, PHASE III STUDY OF ENTRECTINIB VERSUS CRIZOTINIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON SMALL CELL LUNG CANCER HARBOURING ROS1 GENE REARRANGEMENTS WITH AND WITHOUT CENTRAL NERVOUS SYSTEM METASTASES.